Search Results - "Chen, Xiewan"

  • Showing 1 - 19 results of 19
Refine Results
  1. 1

    Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) by Diao, Bo, Wang, Chenhui, Tan, Yingjun, Chen, Xiewan, Liu, Ying, Ning, Lifen, Chen, Li, Li, Min, Liu, Yueping, Wang, Gang, Yuan, Zilin, Feng, Zeqing, Zhang, Yi, Wu, Yuzhang, Chen, Yongwen

    Published in Frontiers in immunology (01-05-2020)
    “…The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed great threat to human…”
    Get full text
    Journal Article
  2. 2

    Characterization of zinc finger protein 536, a neuroendocrine regulator, using pan-cancer analysis by Zeng, Longjin, Zhang, Longyao, Yin, Chenrui, Chen, Xu, Chen, Xiewan, Sun, Lingyou, Sun, Jianguo

    Published in European journal of medical research (08-05-2024)
    “…Previous studies suggested that zinc finger protein 536 (ZNF536) was abundant in the central brain and regulated neuronal differentiation. However, the role of…”
    Get full text
    Journal Article
  3. 3

    RNA sequencing identifies lung cancer lineage and facilitates drug repositioning by Zeng, Longjin, Zhang, Longyao, Li, Lingchen, Liao, Xingyun, Yin, Chenrui, Zhang, Lincheng, Chen, Xiewan, Sun, Jianguo

    Published in PeerJ (San Francisco, CA) (24-09-2024)
    “…Recent breakthrough therapies have improved survival rates in non-small cell lung cancer (NSCLC), but a paradigm for prospective confirmation is still lacking…”
    Get full text
    Journal Article
  4. 4

    A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma by Cui, Tianxiang, Diao, Xinwei, Chen, Xiewan, Huang, Shaojiang, Sun, Jianguo

    Published in BMC cancer (27-07-2016)
    “…Sorafenib is the standard first-line therapy for hepatocellular carcinoma (HCC) and probably ectopic hepatocellular carcinoma (EHCC) as well. No report…”
    Get full text
    Journal Article
  5. 5

    Clinical associations and prognostic value of site-specific metastases in non-small cell lung cancer: A population-based study by Xu, Zihan, Yang, Qiao, Chen, Xiewan, Zheng, Linpeng, Zhang, Luping, Yu, Yongxin, Chen, Mingjing, You, Qiai, Sun, Jianguo

    Published in Oncology letters (01-06-2019)
    “…The prognosis of non-small cell lung cancer (NSCLC) is poor, particularly for patients with metastatic disease. Numerous efforts have been made to improve the…”
    Get full text
    Journal Article
  6. 6

    Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population‐based analysis by Yang, Qiao, Xu, Zihan, Chen, Xiewan, Zheng, Linpeng, Yu, Yongxin, Zhao, Xianlan, Chen, Mingjing, Luo, Bangyu, Wang, Jianmin, Sun, Jianguo

    Published in Thoracic cancer (01-04-2019)
    “…Background The study was conducted to compare the clinicopathological characteristics, survival outcomes, and metastatic patterns between pulmonary large cell…”
    Get full text
    Journal Article
  7. 7

    Immune Response on Optimal Timing and Fractionation Dose for Hypofractionated Radiotherapy in Non-Small-Cell Lung Cancer by Zhao, Xianlan, Li, Jixi, Zheng, Linpeng, Yang, Qiao, Chen, Xu, Chen, Xiewan, Yu, Yongxin, Li, Feng, Cui, Jianxiong, Sun, Jianguo

    Published in Frontiers in molecular biosciences (24-01-2022)
    “…The intervention timing of immune checkpoint inhibitors (ICIs) and radiotherapy fractionations are critical factors in clinical efficacy. This study aims to…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Induced cancer stem cells generated by radiochemotherapy and their therapeutic implications by Chen, Xiewan, Liao, Rongxia, Li, Dezhi, Sun, Jianguo

    Published in Oncotarget (07-03-2017)
    “…Local and distant recurrence of malignant tumors following radio- and/or chemotherapy correlates with poor prognosis of patients. Among the reasons for cancer…”
    Get full text
    Journal Article
  10. 10

    Concurrent EGFR‐TKI and Thoracic Radiotherapy as First‐Line Treatment for Stage IV Non‐Small Cell Lung Cancer Harboring EGFR Active Mutations by Zheng, LinPeng, Wang, Yanmei, Xu, Zihan, Yang, Qiao, Zhu, Guangkuo, Liao, Xing‐Yun, Chen, Xiewan, Zhu, Bo, Duan, Yuzhong, Sun, Jianguo

    Published in The oncologist (Dayton, Ohio) (01-08-2019)
    “…Lessons Learned This single‐arm, phase II study shows that concurrent EGFR‐tyrosine kinase inhibitor plus thoracic radiotherapy as the first‐line treatment for…”
    Get full text
    Journal Article
  11. 11

    Population-based high-dimensional analyses identify multiple intrinsic characters for cancer vaccines against lung squamous cell carcinoma by Zeng, Longjin, Li, Lingchen, Liao, Xingyun, Zhang, Lincheng, Yin, Chenrui, Chen, Xiewan, Sun, Jianguo

    “…In lung squamous cell carcinoma (LUSC), current cancer vaccines show promising effects, despite a lack of benefit for a large number of patients. We first…”
    Get full text
    Journal Article
  12. 12

    High-resolution transcriptomics analysis of CXCL13 + EPSTI1 + CDK1 + cells with a specific focus on lung adenocarcinoma by Zeng, Longjin, Chen, Xu, Cui, Jianxiong, Zhang, Longyao, Li, Lingchen, Yin, Chenrui, Chen, Xiewan, Sun, Jianguo

    Published in Journal of thoracic disease (30-01-2024)
    “…Programmed cell death ligand 1 (PD-L1) blocking therapy has transformed the treatment of lung adenocarcinoma (LUAD), which has significantly changed the…”
    Get full text
    Journal Article
  13. 13

    Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation by Li, Yan, Wang, Yanmei, Niu, Kai, Chen, Xiewan, Xia, Liqin, Lu, Dingxi, Kong, Rui, Chen, Zhengtang, Duan, Yuzhong, Sun, Jianguo

    Published in Oncotarget (25-10-2016)
    “…Acquired resistance is a bottleneck that restricts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) for lung cancer…”
    Get full text
    Journal Article
  14. 14
  15. 15
  16. 16

    Clinical benefits of Livin peptide-loaded DCs/CIKs combined with chemotherapy in advanced non-small cell lung cancer by Zhang, Luping, Xu, Zihan, Chen, Xiewan, Duan, Yuzhong, Chen, Zhengtang, Sun, Jianguo

    Published in American journal of cancer research (01-01-2019)
    “…Previous studies showed that Livin, a member of inhibitors of apoptosis protein (IAP), played an important role in drug and radiation resistance. When the…”
    Get full text
    Journal Article
  17. 17
  18. 18
  19. 19

    Molecular mechanism of microRNA involvement in genesis of myelodysplastic syndrome and its transformation to acute myeloid leukemia by Liao, Rongxia, Xu, Yanmei, Chen, Min, Chen, Xiewan, Zhan, Xiaoqing, Sun, Jianguo

    Published in Hematology (Luxembourg) (01-07-2013)
    “…Myelodysplastic syndrome (MDS) is a group of blood-related malignancies caused by disorders of hematopoietic stem cells (HSCs). It is mainly characterized by…”
    Get more information
    Journal Article